Qualifying Osteogenic Potency Assay Metrics for Human Multipotent Stromal Cells: TGF-β2 a Telling Eligible Biomarker

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Biomarker Discovery

Background:

• Human multipotent stromal cells (hMSC) exhibit functional heterogeneity, posing challenges for regenerative medicine.
• Standardized potency assays are essential for hMSC expansion and clinical application.
• Previous assays relied on five gene biomarkers (ALPL, COL1A2, DCN, ELN, RUNX2) with limitations.

Purpose of the Study:

• To enhance the reproducibility of osteogenic potency assays for hMSC.
• To explore the applicability of modified assays to bone marrow-derived (hBM-MSC) and adipose tissue-derived (hAT-MSC).
• To identify additional biomarkers for improved discrimination of hMSC heterogeneity.

Main Methods:

• Modified real-time PCR assays using a potent osteogenic induction factor and GUSB/YWAHZ reference genes.
• Tested assay reproducibility with six hBM-MSC donors and applicability to three hAT-MSC donors.
• Analyzed mRNA induction of extracellular matrix proteins and TGFB2.
• Evaluated protein expression of decorin and TGF-β2 in heterotopic bone implants.

Main Results:

• Novel assay conditions confirmed the informativeness of extracellular matrix genes one week post-induction.
• TGFB2 mRNA induction was readily quantifiable in both hBM-MSC and hAT-MSC.
• Combined DCN and TGFB2 mRNA induction effectively resolved donor-specific hMSC heterogeneity.
• Protein expression patterns of decorin and TGF-β2 in bone implants also discriminated hMSC sources.

Conclusions:

• Progress has been made towards prompt osteogenic potency assays for hMSC.
• The refined assay, incorporating TGFB2 and DCN, offers improved discriminatory power.
• These advancements are vital for current clinical trials to accelerate stem cell therapy for bone fractures.